2021 BRN Discussion, page-472

This morning I posted the following post. It relates to the peer reviewed confirmation that NaNose's sensor can detect lung cancer. NaNose is partnering with Brainchip. Brainchip has brought on board Professor Barry Marshall Nobel Laurette who has a stated interest in the development of an exhaled breath VOC detection device for diseases including cancer and in multiple company announcements the CEO of Brainchip on behalf of the Board has stated that AKIDA will power the identification of disease including cancer from VOC's on exhaled breath. I have posted the following under 2021 Discussion and will not accept that it is off topic:

Some earlier peer reviewed and published research involving Professor Haick and NaNose detection:

ARTICLE CITATION

DOI:10.1200/jco.2010.28.15_suppl.10521 Journal of Clinical Oncology -published online before print May 20, 2010

Use of a nanoparticle-based artificial olfactory system, NaNose, todistinguish malignant from benign pulmonary noduleAbstract

N.Peled , M.Hakim , H.Haick , P.A. Bunn , Y.E. Miller , T.C. Kennedy...

10521

Background: There is noapproved screening method for lung cancer and CT scanning has a high rate offalse positives. Exhaled breath analysis for volatile organic compounds (VOCs)has the potential to distinguish between benign and malignant nodules.Recently, we showed that novel gold (Au) nanoparticles-based ArtificialOlfactory System; NaNose, distinguishes between malignant (non-small lungcancer; NSCLC) and non-malignant human breaths and cell lines. In this study weincorporated the NaNose in our pulmonary “nodule clinics” where patients areevaluated for a suspicious lung nodule.

Methods: 34 patientswith lung nodules and 21 healthy subjects were tested for exhaled breath VOCprofile. Patients were further evaluated as clinically appropriate. The exhaledbreath was sampled by Eco Medics collecting system and the air passed through aTenax SKC tube, which was analyzed for: (i) gas-chromatography/mass-spectrometry (GCMS) combined with solid phase micro-extraction (SPME) fordetermining the chemical nature of the VOCs; and by (ii) NaNose (Technion,Haifa Israel), for obtaining simple, real-time discriminations between thesamples. For the latter, the electrical properties of the sensors were measuredby a programmed time-related analyzer. Samples from healthy subjects were usedto standardize the signals.

Results: 25 patients hada malignant nodule (23 NSCLC; 12 adenocarcinomas, 8 squamous cell carcinomas, 3undifferentiated and 2 SCLC) and 9 had benign nodules. Smoking history,comorbidity and nodule location were not different between the groups.Principle component analysis of the nanoparticle-based sensors yielded asignificant discrimination between the malignant and the benign nodules (p <0.007; sensitivity 88%; specificity 90%). The SPME/GCMS analysis identified1000 different VOCs, but forward stepwise discrimination analysis produceddifferent VOCs profile for the groups. VOCs that did not overlap between themalignant and the benign groups were isolated and selected as “malignant lungnodule” biomarkers.

Conclusions: Non-invasive,exhaled breath analysis using the NaNose for VOCs profile discriminates betweenmalignant and benign pulmonary nodules.

No significantfinancial relationships to disclose.